An investigation into the association of plasmid-borne qacAB and antimicrobial resistance in meticillin-resistant Staphylococcus aureus by Khan, Azra
 
 
 
 
 
 
 
 
An Investigation into the association of plasmid-borne 
qacAB and antimicrobial resistance in Meticillin-
Resistant Staphylococcus aureus 
 
 
 
 
Azra Khan MSc BSc (Hons) CSci FIBMS 
 
September 2013 
 
 
 
 
A thesis submitted in partial fulfilment of the 
 Degree of Professional Doctorate in Biomedical Science,  
School of Pharmacy and Biomedical Sciences  
 
 
 
University of Portsmouth 
Faculty of Science
i 
 
Abstract 
 Meticillin-resistant Staphylococcus aureus (MRSA) is globally recognised as a 
major causative organism of hospital acquired infection (HAI) and continues to present 
many challenges for infection prevention and control. Once established within hospitals 
and healthcare centers, the control of spread of MRSA and therapy is difficult due to 
resistance to otherwise effective antimicrobials. Government initiatives in the United 
Kingdom (UK) have led to considerable investments in improving infection control 
practices, with emphasis on improving hand hygiene compliance of healthcare 
professionals and hospital environmental cleanliness to control the spread and limit the 
source of MRSA and other HAIs. This has resulted in the subsequent increase in 
disinfectant and antiseptic usage containing, quaternary ammonium compounds (QACs), 
cationic biocides such as chlorhexidine and the bisphenol ether, triclosan, for 
decontamination of surfaces and disinfection of skin. Thus, there is serious concern that as 
with antibiotic resistance, continual and intensive exposure of MRSA (and other hospital 
pathogens) to biocides, may result in the emergence of resistance to these agents with 
further detrimental consequences and substantial burden for prevention, treatment and 
control of hospital infections.  
 
 MRSA carry a number of plasmid-borne qac genes, predominantly qacA, qacB and 
smr that encode resistance to commonly used antiseptics and disinfectants in hospitals, 
nursing homes and other healthcare establishments. The proteins encoded by qacA and 
qacB mediate efflux via active transport; QacA multidrug exporter mediates resistance to 
monovalent, divalent cationic and lipophilic antimicrobial compounds, whilst the closely 
related export protein QacB mediates lower levels of resistance to divalent cations.  
 In this research a “snapshot” study of hospital strains of MRSA stored at the 
Hospital Infection Research Laboratory (HIRL), City Hospital, Birmingham, was carried 
out to determine the prevalence and distribution of qacAB in these isolates and determine a 
possible association between presence of these genes and biocide resistance. The 
intercalating dye, ethidium bromide (EtBr) is a substrate for many S. aureus multi-drug 
resistant (MDR) efflux pumps and was used in the present study as a marker for detection 
of efflux pump activity. Previous studies have reported that MRSA strains with an MIC of 
≥ 64 mg/L to EtBr have qacAB, however, the present study used a lower baseline value of 
≥ 32 mg/L resistance to EtBr to capture any isolates with low MICs that may have qacAB 
and may be missed.   
 Initially 3,400 MRSA strains collected between October 2002 and October 2006 
were screened to identify and select isolates with ≥ 32 mg/L resistance to EtBr. A second 
MRSA collection stored at the Antimicrobial Chemotherapy Laboratory, City Hospital, 
Birmingham, comprised 63 isolates that showed MICs of ≥ 64mg/L, were also included in 
the study. At this stage the study set (Set A) comprised 112 isolates with varying MIC to 
EtBr ranging from ≥ 32 mg/L to 256 mg/L. At a later date an additional 400 strains were 
screened from the same stored collection to include strains with lower MICs, i.e. < 32 
mg/L. Thus a total of 336 isolates with varying levels of resistance to EtBr were studied. 
 PCR was carried out on all 336 isolates for detection of qacAB, smr, qacG, qacH 
and qacJ to determine the presence and prevalence of the genes. Set A isolates positive for 
qacAB were further investigated to differentiate between qacA and qacB. Restriction 
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digestion using the restriction enzyme Rsa1 was carried out on PCR products followed by 
PCR using specific primers for detection of the two genes. Urease activity and neomycin 
sensitivity were used as a means of basic characterization applied to all the study isolates. 
A select number of samples negative for qacA and qacB were typed using spa typing.   
 
 Transfer studies involving, conjugation, plate mating and transformation on 
selected strains were carried out to attempt transfer of qacAB using the marker EtBr from a 
strain of MRSA with an MIC of  ≥ 256 mg/L to EtBr and qacAB positive to a strain with   
< 32mg/L MIC to EtBr and lacking qacAB. Unfortunately, conjugation experiments were 
not successful in this study. Plasmid curing experiments were also carried out to 
demonstrate loss of plasmid through continual passaging onto selective plates.  
 
 A variety of antiseptics and disinfectants are used in hospitals for prevention of 
HAIs. The present study was limited to carrying out minimum bactericidal concentration 
(MBC) determinations and MIC of four commonly used hospital biocides against 
randomly selected strains. The strains reflected ranges of MICs to EtBr and presence or 
absence of qacAB. These experiments, determined the efficacy of the biocides tested, to 
effectively destroy MRSA on skin and environment when used in healthcare settings.  
 
 The results suggest that in the majority of strains showing high MICs to EtBr i.e. ≥ 
64 mg/L, qacAB is present and thus, the mechanism of resistance to biocides may be 
attributed to an efflux protein pump encoded by these genes. Following restriction 
digestion of qacAB positive strains, with the restriction enzyme Rsa1, 81 of the 112 qacAB 
positive strains tested positive for qacA, i.e. 90% and 9 (11%) for qacB. The predominant 
prevalence of the qacA gene indicates that most of these strains are likely to be resistant to 
organic cationic biocides and intercalating dyes such as EtBr and acriflavine. However, the 
results of the MIC and MBC determinations carried out on a selection of biocides 
commonly used in the healthcare environment implies that the four biocides tested are 
likely to be 99.9% effective at killing the majority of isolates in this study set. However, 
five isolates demonstrated MBCs to chlorhexidine of > 32 mg/L. Chlorhexidine is a 
compound that is widely used in hand hygiene and surgical antisepsis products, and the 
results suggest that solutions containing this compound would be ineffective in removing 
MRSA from the hands of healthcare workers and skin sites if used. 
 
 Molecular spa typing of selected samples negative for qacAB revealed that 
Endemic-MRSA (EMRSA) type 15 was the most frequent spa type identified in this study, 
followed by EMRSA-16 and EMRSA-1. Three strains identified jointly as EMRSA-3 and 
EMRSA-1. One strain identified as the Berlin clone 
 
 
 With regards to the challenges presented to infection prevention and control, 
MRSA has the potential to develop increased tolerance to biocides commonly used in the 
hospital environment, due to expression of efflux pumps, although currently there is little 
evidence of this. Further research is required to understand and learn of the various 
mechanisms of resistance, supported by adherence to control of infection strategies for 
prevention and spread of infections in healthcare facilities. 
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